New treatments for chronic hepatitis B using long-acting medications
New generation of long acting nucleos(t)ides and immune stimulant for treatment of chronic hepatitis B
This study is testing a new type of long-lasting injection for people with chronic hepatitis B that could replace daily pills, making treatment easier and more effective by combining special medications to help your body fight the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11042702 on NIH RePORTER |
What this research studies
This research focuses on developing a new generation of long-acting injectable medications for chronic hepatitis B (CHB) that could replace the need for daily pills. By combining nucleos(t)ide analogs with immune-stimulating compounds, the goal is to create a treatment that can be administered every two months. The approach involves formulating these drugs into nanosuspensions to enhance their effectiveness and ensure they are absorbed efficiently by the liver. This innovative method aims to achieve sustained viral suppression and potentially a functional cure for CHB.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic hepatitis B who are currently on antiviral therapy or are in need of treatment.
Not a fit: Patients who do not have chronic hepatitis B or those who are not eligible for antiviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the treatment of chronic hepatitis B, reducing the burden of the disease and its complications.
How similar studies have performed: Previous research has shown promise in using long-acting antiviral therapies for other conditions, suggesting potential success for this novel approach in chronic hepatitis B.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Poluektova, Larisa Y — University of Nebraska Medical Center
- Study coordinator: Poluektova, Larisa Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.